Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 23 | 2024 | 790 | 3.290 |
Why?
|
| T-Lymphocytes | 22 | 2024 | 1678 | 2.430 |
Why?
|
| Cell- and Tissue-Based Therapy | 8 | 2024 | 154 | 1.750 |
Why?
|
| Herpesvirus 4, Human | 6 | 2024 | 663 | 1.580 |
Why?
|
| Antigens, CD19 | 10 | 2024 | 177 | 1.470 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2024 | 223 | 1.450 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2024 | 479 | 1.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2024 | 1192 | 1.390 |
Why?
|
| Genetic Therapy | 3 | 2024 | 706 | 1.330 |
Why?
|
| Hematologic Neoplasms | 3 | 2023 | 271 | 1.300 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2024 | 284 | 1.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 122 | 1.140 |
Why?
|
| Killer Cells, Natural | 4 | 2018 | 325 | 1.110 |
Why?
|
| Leukemia | 2 | 2024 | 375 | 0.860 |
Why?
|
| Lymphoma | 3 | 2024 | 323 | 0.840 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 184 | 0.820 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 581 | 0.780 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2024 | 262 | 0.700 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 548 | 0.700 |
Why?
|
| Poverty | 1 | 2023 | 412 | 0.670 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 146 | 0.650 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2023 | 803 | 0.620 |
Why?
|
| Immunotherapy | 3 | 2023 | 658 | 0.620 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2018 | 532 | 0.610 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 261 | 0.540 |
Why?
|
| Immune Evasion | 1 | 2015 | 31 | 0.510 |
Why?
|
| Receptors, KIR | 1 | 2015 | 9 | 0.510 |
Why?
|
| Smad Proteins | 1 | 2015 | 43 | 0.510 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 431 | 0.500 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2015 | 47 | 0.490 |
Why?
|
| Lymphoma, B-Cell | 3 | 2023 | 137 | 0.490 |
Why?
|
| Humans | 48 | 2024 | 122296 | 0.480 |
Why?
|
| Patient Safety | 1 | 2019 | 389 | 0.480 |
Why?
|
| Siblings | 1 | 2015 | 191 | 0.470 |
Why?
|
| Virus Activation | 1 | 2014 | 86 | 0.460 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 269 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 218 | 0.430 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 458 | 0.430 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 65 | 0.370 |
Why?
|
| CD5 Antigens | 2 | 2024 | 37 | 0.360 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 386 | 0.350 |
Why?
|
| Child | 17 | 2024 | 24064 | 0.340 |
Why?
|
| Young Adult | 11 | 2024 | 8760 | 0.330 |
Why?
|
| Adolescent | 14 | 2024 | 18940 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2020 | 162 | 0.300 |
Why?
|
| Neoplasms | 4 | 2024 | 2753 | 0.290 |
Why?
|
| Minority Groups | 2 | 2024 | 249 | 0.260 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 87 | 0.240 |
Why?
|
| Hematology | 1 | 2024 | 36 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 768 | 0.230 |
Why?
|
| Rituximab | 1 | 2024 | 157 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 137 | 0.210 |
Why?
|
| Graft vs Host Disease | 2 | 2019 | 542 | 0.210 |
Why?
|
| Bone Marrow Diseases | 1 | 2022 | 38 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2024 | 163 | 0.200 |
Why?
|
| Male | 13 | 2024 | 59522 | 0.200 |
Why?
|
| Adult | 12 | 2024 | 28733 | 0.200 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 141 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 874 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 492 | 0.200 |
Why?
|
| Antigens, CD7 | 2 | 2018 | 11 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 323 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 333 | 0.180 |
Why?
|
| Female | 14 | 2024 | 64883 | 0.170 |
Why?
|
| Cytokines | 4 | 2022 | 1272 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 398 | 0.170 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 29 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2021 | 193 | 0.160 |
Why?
|
| Pyridazines | 1 | 2019 | 49 | 0.160 |
Why?
|
| Vaccinia virus | 1 | 2019 | 52 | 0.160 |
Why?
|
| Imidazoles | 1 | 2019 | 200 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 355 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 69 | 0.140 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 659 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1118 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1076 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2017 | 159 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 322 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2019 | 576 | 0.130 |
Why?
|
| Child, Preschool | 6 | 2024 | 13777 | 0.120 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2014 | 2 | 0.120 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 21 | 0.120 |
Why?
|
| Vaccination | 1 | 2019 | 927 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 208 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2015 | 810 | 0.110 |
Why?
|
| Immunologic Memory | 1 | 2014 | 180 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2015 | 1613 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3229 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 1458 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5013 | 0.090 |
Why?
|
| Leukocytosis | 1 | 2011 | 42 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2019 | 680 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2024 | 673 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2013 | 404 | 0.090 |
Why?
|
| Biomarkers | 2 | 2017 | 2933 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 506 | 0.090 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 90 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 3307 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12045 | 0.080 |
Why?
|
| Infant, Premature, Diseases | 1 | 2011 | 239 | 0.080 |
Why?
|
| Down Syndrome | 1 | 2011 | 194 | 0.080 |
Why?
|
| Animals | 8 | 2024 | 33721 | 0.080 |
Why?
|
| Myeloid Cells | 2 | 2018 | 100 | 0.070 |
Why?
|
| Mice | 6 | 2022 | 17546 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2017 | 4511 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2024 | 1166 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2019 | 2311 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 297 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 15853 | 0.060 |
Why?
|
| United States | 3 | 2024 | 10487 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 12302 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 234 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 469 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 122 | 0.060 |
Why?
|
| Personnel Selection | 1 | 2024 | 62 | 0.060 |
Why?
|
| Middle Aged | 5 | 2024 | 25640 | 0.060 |
Why?
|
| Career Choice | 1 | 2024 | 143 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 147 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 87 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 142 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2014 | 333 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 18785 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 1579 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2023 | 539 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 230 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2022 | 570 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 318 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 394 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 170 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 3290 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 239 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 32 | 0.040 |
Why?
|
| Retroviridae | 1 | 2019 | 205 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 98 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 235 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 541 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 228 | 0.040 |
Why?
|
| Prognosis | 2 | 2021 | 4488 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 109 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2019 | 240 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 72 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 300 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 738 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 58 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 152 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 4282 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 257 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2019 | 637 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 236 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1790 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2019 | 969 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1413 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 39 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 978 | 0.030 |
Why?
|
| Pediatrics | 1 | 2024 | 1140 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1247 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2014 | 5 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2014 | 12 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2014 | 16 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2014 | 17 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 30 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 114 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2014 | 79 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 165 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 70 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 43 | 0.030 |
Why?
|
| WT1 Proteins | 1 | 2013 | 27 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 170 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 119 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 212 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 812 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 508 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 749 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 745 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 665 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 3074 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6291 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 5734 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2011 | 799 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 7092 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8096 | 0.010 |
Why?
|